CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- FinancialsAltman Z-Score 2.31: grey zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
950.29MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
1.17xvs all stocks
52-Week Change
134.82%vs all stocks
Market Capitalization
950.29MUSDvs all stocks (USD)
Enterprise Value
765.44MUSDvs all stocks (USD)
Forward P/E
-6.38xvs Biotechnology peers
Price to Book (MRQ)
4.68xvs Biotechnology peers
Enterprise to EBITDA
-3.77xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-45.29%vs Biotechnology peers
Return on Equity (TTM)
-87.65%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Jul 18, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-202.89MUSDvs all stocks (USD)
Net Income (TTM)
-198.33MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-183.10MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-107.34MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 18, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-216.41MUSDvs all stocks (USD)
Pre-tax Income
-206.69MUSDFY2025 · Dec 31, 2025Net Income
-206.69MUSDFY2025 · Dec 31, 2025EBIT
-216.41MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-213.76MUSDFY2025 · Dec 31, 2025Research & Development
184.70MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
29.06MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
9.72MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-206.69MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-190.17MUSDFY2025 · Dec 31, 2025Free Cash Flow
-190.31MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
163.08MUSDFY2025 · Dec 31, 2025Income Tax Paid
5.07MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-206.69MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
2.17MUSDFY2025 · Dec 31, 2025Stock-based Compensation
16.42MUSDFY2025 · Dec 31, 2025Other Non-cash Items
1.52MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
4.49MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-8.08MUSDFY2025 · Dec 31, 2025Capital Expenditures
-137.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-212.21MUSDFY2025 · Dec 31, 2025Sale of Investments
402.40MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
190.05MUSDFY2025 · Dec 31, 2025Other Financing Charges
-1.62MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
107.94MUSDFY2025 · Dec 31, 2025Shares Outstanding
162.50MSharesUpdated Jul 18, 2026Float Shares
129.36MSharesUpdated Jul 18, 2026Shares Short
29.60MSharesUpdated Jul 18, 2026Short Ratio
7.16daysvs all stocks
Short % of Shares Outstanding
19.30%vs all stocks
% Held by Insiders
0.49%vs all stocks
% Held by Institutions
102.39%vs all stocks
Total Cash (MRQ)
225.02MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
1.37USDUpdated Jul 18, 2026Total Debt (MRQ)
25.43MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.1244xvs Biotechnology peers
Current Ratio (MRQ)
6.35xvs Biotechnology peers
Book Value per Share (MRQ)
1.26USDUpdated Jul 18, 2026Total Assets
277.57MUSDvs all stocks (USD)
Total Current Assets
242.19MUSDFY2025 · Dec 31, 2025Total Liabilities
65.92MUSDFY2025 · Dec 31, 2025Total Non-current Assets
35.38MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
23.29MUSDFY2025 · Dec 31, 2025Total Current Liabilities
42.63MUSDFY2025 · Dec 31, 2025Cash
2.01MUSDFY2025 · Dec 31, 2025Cash Equivalents
160.04MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
162.05MUSDFY2025 · Dec 31, 2025Other Short-term Investments
76.29MUSDFY2025 · Dec 31, 2025Accounts Payable
14.93MUSDFY2025 · Dec 31, 2025Short-term Debt
2.91MUSDFY2025 · Dec 31, 2025Other Current Liabilities
509.00KUSDFY2025 · Dec 31, 2025Long-term Debt
23.29MUSDFY2025 · Dec 31, 2025Common Stock (Book)
149.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-917.39MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
211.65MUSDvs all stocks (USD)
52-Week Low
2.03USDUpdated Jul 18, 202652-Week High
7.18USDUpdated Jul 18, 202652-Week Change
134.82%vs all stocks
Beta
1.17xvs all stocks
50-Day MA
5.40USDUpdated Jul 18, 2026200-Day MA
5.01USDUpdated Jul 18, 2026Avg 10-Day Volume
5.54MSharesUpdated Jul 18, 2026Avg 30-Day Volume
4.68MSharesUpdated Jul 18, 2026Diluted EPS (TTM)
-1.09USDUpdated Jul 18, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 2.31: grey zoneSignificant
Altman Z-Score: 2.31
Low earnings qualitySignificant
Earnings Quality Score: -0.73
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Beijing Tong Ren Tang Chinese Medicine Company Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Guizhou Bailing Group Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Green Cross Corporation
Tier 1ProductionApproval-Gated PipelineRule
Youcare Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Tianjin Tianyao Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hob Biotech Group Suzhou Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Kura Oncology Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Arbutus Biopharma Corporation
Tier 1ProductionApproval-Gated PipelineRuleRisk
Suven Life Sciences Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Seegene, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Olaplex Holdings, Inc.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Hebei Sinopack Electronic Co., Ltd.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Samsung Electronics Co., Ltd.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity